Colorectal Cancer | Specialty

Dr. Overman on Implications of Tumor Location Data for Patients With mCRC

July 11th 2016

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses how the results of the phase III FIRE-3 and 80405 studies will impact treatment of patients with metastatic colorectal cancer.

Dr. Volker Heinemann on the Addition of SIRT to Chemotherapy for mCRC

July 8th 2016

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response, which is highly correlated with overall survival, was improved for patients with metastatic colorectal cancer who added selective internal radiation therapy (SIRT) to chemotherapy.

First-Line Cetuximab Combo Validated in RAS Wild-Type Colorectal Cancer

July 3rd 2016

The addition of cetuximab to standard FOLFOX-4 chemotherapy in the first-line treatment of patients with RAS wild-type metastatic colorectal cancer significantly improved survival outcomes.

MABp1 Improves Symptoms in Phase III CRC Study

July 3rd 2016

MABp1, a novel anti–interleukin 1-alpha antibody, was safe, well-tolerated, and demonstrated a significant impact on symptoms compared with placebo for patients with advanced colorectal cancer.

SIRT Improves Depth of Response in mCRC Patients With Liver Mets

July 1st 2016

Adding selective internal radiation therapy with SIR-Spheres Y-90 resin microspheres to standard first-line chemotherapy significantly increased hepatic depth of response in patients with metastatic colorectal cancer.

Dr. Berger on the Significance of the Cologuard Screening Test

July 1st 2016

Barry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses the significance and benefits of the Cologuard screening test for colorectal cancer.

Dr. Yurgelun on Susceptibility Gene Mutations in CRC

June 30th 2016

Daniel Sargent on International Collaboration for Colon Cancer Research

June 30th 2016

Daniel Sargent, PhD, professor of Oncology and Biostatistics, Mayo Clinic in Rochester, Minnesota, discusses the IDEA initiative, which is an international study to examine if patients with colon cancer would benefit from reducing the duration of adjuvant therapy from 3 months to 6 months to reduce side effects and cost.

Cobimetinib Plus Atezolizumab Active in Microsatellite Stable mCRC

June 29th 2016

Combined inhibition of the PD-L1/PD-1 axis with atezolizumab (Tecentriq) and the MEK pathway with cobimetinib (Cotellic) showed promising clinical activity and a good safety profile in heavily pretreated patients with microsatellite stable metastatic colorectal cancer.

Dr. Raghav on HER2 Amplification in Patients With CRC

June 24th 2016

Kanwal Raghav, MBBS, MD, assistant professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining HER2 gene amplification in patients with metastatic colorectal cancer.

Expert Sheds Light on Promising Immunotherapy Combo Data in mCRC

June 23rd 2016

Michael J. Overman, MD, discusses the findings of the phase II CheckMate-142 study, which examined nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with high microsatellite instability colorectal cancer.

USPSTF Updates CRC Screening Guideline

June 21st 2016

The United States Preventative Services Task Force recommends screening for colorectal cancer using traditional colonoscopy or one of 7 tests at various frequencies for all patients aged 50 to 75.

Dr. Overman on Nivolumab and Ipilimumab in Patients With MSI-H CRC

June 15th 2016

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) monotherapy, ipilimumab (Yervoy) monotherapy, and the combination of nivolumab and ipilimumab in patients with high microsatellite instability metastatic colorectal cancer.

Atezolizumab and Cobimetinib Regimen Shows Activity in CRC

June 15th 2016

In patients with advanced colorectal cancer, the combination regimen of cobimetinib (Cotellic) and atezolizumab (Tecentriq) was found to demonstrate clinical activity as well as have a good safety profile.

Process Unclear on How to Identify Mutations in Non-Lynch Syndrome Patients With CRC

June 9th 2016

Results of an analysis presented at the 2016 ASCO Annual Meeting demonstrate the difficulty in determining the prevalence of germline cancer susceptibility gene mutations in patients with colorectal cancer (CRC) who do not harbor Lynch syndrome.

Nivolumab/Ipilimumab Combo Active in Microsatellite Instability-High mCRC

June 6th 2016

Nivolumab (Opdivo) as a monotherapy and in combination with ipilimumab (Yervoy) demonstrated promising antitumor activity in patients with high microsatellite instability (MSI-H) metastatic colorectal cancer.

Expert Shares Significance of Approved Agents in CRC

June 2nd 2016

Tanios Bekaii-Saab, MD, discusses the use of both regorafenib and TAS-102, as well as the potential role immunotherapy could have within colorectal cancer.

Polyp Mutations May Hold Key to CRC Prevention

May 31st 2016

Precancerous colon polyps exhibit many of the same driver mutations that fuel the development of colorectal cancer.

Tumor Location Linked to Survival Outcomes in Metastatic Colorectal Cancer

May 19th 2016

Survival outcomes in patients with metastatic colorectal cancer were significantly longer among those with tumors originating on the left versus the right side of the colon, according to a retrospective analysis of the phase III 80405 trial.

SIRFLOX Study Design Confounds Primary Efficacy Findings

April 27th 2016

Navesh K. Sharma, DO, PhD, discusses findings on a study looking at the addition of Yttrium-90 resin microspheres to standard frontline FOLFOX-based chemotherapy with or without bevacizumab in liver metastatic colorectal cancer.